DES MOINES, Iowa, July 19 /PRNewswire-FirstCall/ -- Healthcare
Acquisition Corp. (AMEX: HAQ), a publicly-traded special purpose
acquisition company, announced that it has scheduled a special meeting of
its stockholders to vote on, among other things, the proposed merger
transaction with PharmAthene, Inc., a biodefense company developing and
commercializing medical countermeasures against biological and chemical
threats. The special meeting will be held on July 27, 2007 at 10:00 a.m.
Eastern Time at the offices of McCarter & English, LLP, 245 Park Avenue,
27th Floor, New York, NY. Other proposals related to the proposed merger
transaction will also be voted on. The record date for stockholders
entitled to vote at the special meeting was fixed at the close of business
on June 15, 2007.
Definitive proxy materials relating to the special meeting were filed
with the U.S. Securities and Exchange Commission on July 13, 2007 and such
materials were mailed to HAQ stockholders of record on or about July 16,
2007. HAQ's stockholders are urged to read the proxy statement and other
relevant materials if and as they become available as they will contain
important information about the proposed merger and the related proposals.
The Board of Directors of HAQ unanimously recommends that stockholders
vote "for" each of the proposals related to the proposed merger
transaction. Additional information about the proposed merger and each of
the other proposals can be found in the definitive proxy statement.
HAQ stockholders with questions about the proposed merger or any of the
other proposals or who need assistance in voting their shares may call the
Company's proxy solicitor, Morrow & Co., Inc., toll-free at (800) 607-0088.
Additional Information
HAQ AND ITS DIRECTORS AND EXECUTIVE OFFICERS AS WELL AS PHARMATHENE AND
ITS DIRECTORS AND EXECUTIVE OFFICERS MAY BE DEEMED TO BE PARTICIPANTS IN
THE SOLICIATION OF PROXIES FOR THE SPECIAL MEETING OF HAQ'S STOCKHOLDERS TO
BE HELD TO APPROVE THE PROPOSED MERGER. SECURITYHOLDERS AND OTHER
INTERESTED PERSONS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT
REGARDING THE PROPOSED MERGER FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION ON JULY 13, 2007, AS THEY WILL CONTAIN IMPORTANT INFORMATION
ABOUT THE PROPOSED MERGER. STOCKHOLDERS WILL ALSO BE ABLE TO OBTAIN A COPY
OF THE DEFINITIVE PROXY STATEMENT, WITHOUT CHARGE, BY DIRECTING A REQUEST
TO HAQ AT: 2116 FINANCIAL CENTER, 666 WALNUT STREET, DES MOINES, IOWA
50309. THE DEFINITIVE PROXY STATEMENT AND THE FINAL PROSPECTUS AND OTHER
SEC FILINGS OF HAQ CAN ALSO BE OBTAINED, WITHOUT CHARGE, AT THE SECURITIES
AND EXCHANGE COMMISSION'S INTERNET SITE (http://www.sec.gov).
HAQ AND PHARMATHENE CLAIM THE PROTECTION OF THE SAFE HARBOR FOR
"FORWARD- LOOKING STATEMENTS" WITHIN THE MEANING OF THE PRIVATE SECURITIES
LITIGATION REFORM ACT OF 1995. FORWARD-LOOKING STATEMENTS ARE STATEMENTS
THAT ARE NOT HISTORICAL FACTS. SUCH FORWARD-LOOKING STATEMENTS, BASED UPON
THE CURRENT BELIEFS AND EXPECTATIONS OF MANAGEMENT OF HAQ AND PHARMATHENE
REGARDING, AMONG OTHER THINGS, THE BUSINESS OF PHARMATHENE AND THE MERGER,
ARE SUBJECT TO RISKS AND UNCERTAINTIES, WHICH COULD CAUSE ACTUAL RESULTS TO
DIFFER FROM THE FORWARD-LOOKING STATEMENTS. RISKS AND UNCERTAINTIES INCLUDE
RISKS ASSOCIATED WITH THE RELIABILITY OF THE RESULTS OF THE INITIAL WORK
CONDUCTED ON VALORTIM(TM) RELATING TO ANIMAL EFFICACY, HUMAN SAFETY AND
LIKELIHOOD OF SUCCESSFUL DEVELOPMENT OF AN EFFICIENT AND SCALABLE
MANUFACTURING PROCESS, UNEXPECTED FUNDING DELAYS BY NIAID, UNFORESEEN
SAFETY ISSUES RESULTING FROM THE HANDLING OF BACILLUS ANTHRACIS, UNFORESEEN
SAFETY ISSUES RESULTING FROM THE ADMINISTRATION OF VALORTIM(TM) (MDX-1303)
IN HUMAN SUBJECTS, UNCERTAINTIES RELATED TO PRODUCT MANUFACTURING. THERE
CAN BE NO ASSURANCE THAT SUCH DEVELOPMENT EFFORTS WILL SUCCEED OR THAT
OTHER DEVELOPED PRODUCTS WILL RECEIVE REQUIRED REGULATORY CLEARANCE OR
THAT, EVEN IF SUCH REGULATORY CLEARANCE WERE RECEIVED, SUCH PRODUCTS WOULD
ULTIMATELY ACHIEVE COMMERCIAL SUCCESS.
About Healthcare Acquisition Corp.
Des Moines-based Healthcare Acquisition Corp. was jointly formed by
healthcare investing pioneers, John Pappajohn and Derace L. Schaffer, M.D.
Healthcare Acquisition Corp. is a special purpose acquisition company
focused on the healthcare industry. The Company raised $75.2 million
through an IPO in July, 2005. As of September 30, 2006, the Company held
approximately $70 million in trust. The Company's shares trade on the
American Stock Exchange, under the symbol HAQ and its warrants trade on the
American Stock Exchange under the symbol HAQW.
About PharmAthene, Inc.
PharmAthene, a privately-held biodefense company, was formed in 2001 to
meet the critical needs of the United States by developing biodefense
products. PharmAthene is dedicated to the rapid development of important
and novel biotherapeutics to address biological pathogens and chemicals
that may be used as weapons of bioterror. PharmAthene's lead programs
include Valortim(TM) (being co-developed with Medarex, Inc. (Nasdaq: MEDX)
and Protexia(R). For more information on PharmAthene, please visit its
website at http://www.PharmAthene.com.
SOURCE Healthcare Acquisition Corp.
 back to top
Related links:
http://www.pharmathene.com/
CONTACT:
Matthew Kinley of Healthcare Acquisition
Corp., +1-515-244-5746, kinley@pappajohn.com
|
